Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
August 2, 2023
- Kaken’s Burn Eschar Remover NexoBrid Now Available in Japan
August 2, 2023
- Lonsurf-Bevacizumab Combo Approved in EU for Colorectal Cancer: Taiho
August 2, 2023
- Astellas’ Zolbetuximab Accepted for Review in China for CLDN18.2 Gastric Cancer
August 2, 2023
- AbbVie Merges Allergan in Japan after Global Acquisition
August 2, 2023
- Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
- Astellas to Cut 500 More Jobs in Buyout Targeting Commercial Unit
August 2, 2023
- Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
August 1, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
August 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
August 1, 2023
- Otsuka’s Pharma H1 Sales Zoom 20% as Global Brands Fare Well
August 1, 2023
- Mitsubishi Tanabe Rolls Out Tardive Dyskinesia Drug in Thailand
August 1, 2023
- Zeria’s Swiss Unit Launches JV in US to Develop Oral mAb for Ulcerative Colitis
July 31, 2023
- Novo Seeks Label Expansion of Concizumab for Hemophilia without Inhibitors
July 31, 2023
- UCB Submits Anti-Epileptic Drug Brivaracetam in Japan
July 31, 2023
- Nippon Shinyaku’s DMD Drug Nabs Breakthrough Therapy Designation
July 31, 2023
- Chugai Marks 2-Digit Growth in Core Earnings in H1 on Robust Sales, Exports
July 28, 2023
- Takeda Set to Bring Entyvio Back to Double-Digit Growth in FY2023: Exec
July 28, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…